|
|
|
|
|
Session 50
Poster Presentations Neutralizing Antibodies Session Day and Time: Wednesday 1:30 - 3:30 pm Room: Hall D |
Background: HIV-1 has proven to be an
extremely difficult target for vaccine development, in part because of its
capacity to mutate to escape immunologic recognition. Furthermore, circulating
strains are becoming more and more divergent with time. Thus, one conundrum
facing vaccine developers is the choice of viral strains from which to
formulate immunogens capable of eliciting broad immunity.
Methods: We have designed candidate
vaccines that encompass the common features of present day viruses through reconstruction
of their ancestral states. The ancestral state of the HIV-1 clade B protein
(An1-EnvB) was deduced using maximum likelihood methods, and the gene was
synthesized following human codon usage optimization. gp160 and gp140 versions
of the gene were tested for functionality in transfected COS-7 and GHOST cells.
An1-EnvB DNA was used to immunize rabbits via Gene Gun and tested for
generation of neutralizing antibodies against a variety of primary and
culture-adapted HIV strains in a cMAGI assay.
Results: The human-codon optimized
synthetic ancestral An1-EnvB gene was shown to produce a glycoprotein that
caused fusion of cells expressing the HIV-1 co-receptors CD4 and CCR5, but not
CD4 plus CXCR4. The gp140 form bound to CD4 in vitro. As DNA vaccines, An1-EnvB
gp140 and gp160 elicited antibody titers in rabbits up to 1:100,000. We
measured neutralizing antibody against 2 clade B HIV-1 isolates, SF162 and
92US657, which are heterologous to the immunogen. After 4 immunizations, 50%
neutralization titers against the SF162 strain ranged from 1:5 to 1:11 in 6 of 8
rabbits. Three (3) of those animals had titers of 1:4 at the 75% neutralization
level. Neutralization against the primary viral isolate 92US657 was also seen
in 2 animals at 50% and 90%.
Conclusions: Presentation of
ancestral state features of variable immunogens provides a promising new
approach to strain choice for the generation of HIV vaccines.